<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97263">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01838551</url>
  </required_header>
  <id_info>
    <org_study_id>COR-003</org_study_id>
    <nct_id>NCT01838551</nct_id>
  </id_info>
  <brief_title>Treatment for Endogenous Cushing's Syndrome</brief_title>
  <official_title>An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cortendo AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cortendo AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to evaluate the efficacy of ascending doses of
      COR-003 in subjects with elevated levels of cortisol due to endogenous Cushing's Syndrome by
      assessment of reduction in Urinary Free Cortisol (UFC) concentrations and to identify the
      range of safe and effective doses of COR-003 that reduce mean UFC concentrations ≤ULN (upper
      limit of normal) of the assay at month 6 of the maintenance phase of dosing without a prior
      dose increase in that phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a single period, open-label, dose titration study to assess efficacy, safety,
      tolerability, and PK of COR-003 in subjects with CS. The trial design will identify both the
      minimally effective and maximally tolerated doses in this CS population. Following an
      initial screening period, this study will be conducted in 2 treatment phases as follows:

        -  Dose titration phase: approximately 2 to 16 weeks to achieve an effective and tolerable
           maximum dose (the therapeutic dose)

        -  Maintenance phase: 6 months of treatment at the therapeutic dose without a prior dose
           increase following the establishment of the appropriate dose identified in the
           titration phase;

        -  Extended evaluation phase: 6 months of continued treatment after the maintenance phase
           (6 - 12 months); dose adjustments will be allowed as required for treatment

      Efficacy will be assessed by measuring UFC concentrations at specified times as described in
      the clinical protocol.

      Blood samples for the PK determination will be collected at the times indicated in the
      clinical protocol.

      An independent Data Safety Monitoring Board (DSMB) will review the safety of the drug
      throughout the study. The constituents of the DSMB membership and a adjudication committee
      is specifically described in the clinical protocol.

      Subjects completing the 6-month maintenance phase of the study will remain in the study for
      an additional 6 months for extended evaluations.

      COR-003 will be provided under a compassionate use protocol for subjects who wish to
      continue treatment with COR-003.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in urinary free cortisol in patients with endogenous Cushing's Syndrome.</measure>
    <time_frame>6 months of maintenance phase therapy without a prior dose increase during that phase</time_frame>
    <description>The response to COR-003 is defined as mean UFC concentration ≤ULN following 6 months of maintenance phase therapy without a prior dose increase during that phase.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Endogenous Cushing's Syndrome</condition>
  <arm_group>
    <arm_group_label>COR-003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male or female, ≥18 year of age, or of a minimal age as required by the local regulations with confirmed diagnosis of CS as defined according to the criteria in the guidelines for diagnosis of CS (Nieman 2008).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COR-003</intervention_name>
    <arm_group_label>COR-003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects eligible for enrollment in the study must meet all the following criteria:

          1. Male or female ≥18 years of age

          2. Able to provide written informed consent prior to any study procedures being
             performed; eligible subjects must be able to understand the informed consent form
             prior to inclusion into the study.

          3. Confirmed diagnosis of newly diagnosed, persistent or recurrent CD if subjects are
             not candidates for surgery or radiotherapy CD is defined according to the criteria in
             the Endocrine Society Clinical Practice Guideline for diagnosis of CD (Nieman 2008).
             Previous medical records will be collected and used to support the diagnosis of CD.

             Specifically, CD is defined as

               -  Mean 24-hour UFC level of ≥1.5X ULN on repeated determination

               -  Morning plasma corticotropin (ACTH) level of 5 ng/L (1.1 nmol /L) or more

               -  Either MRI confirmation of pituitary macroadenoma, or inferior petrosal sinus
                  gradient &gt;3 after corticotropin-releasing hormone (CRH) stimulation for those
                  patients with a microadenoma, or for subjects who have had prior pituitary
                  surgery, histopathology confirming and ACTH-staining adenoma. If inferior
                  petrosal sampling had been performed without CRH, then a central to peripheral
                  pre-stimulation gradient &gt;2 is required

          4. Confirmed diagnosis of newly diagnosed, persistent or recurrent endogenous CS of
             other etiology if subjects are not candidates for surgery or radiotherapy. CS will be
             defined according to the criteria in the Endocrine Society Clinical Practice
             Guideline for diagnosis of CS (Nieman 2008). Previous medical records will be
             collected and used to support the diagnosis, and the differentiation of the cause of
             CS, specifically

               -  Mean 24-hour UFC level of ≥1.5X ULN on repeated determination

               -  Ectopic ACTH secretion, not of pituitary origin

               -  Ectopic CRH secretion

               -  Adrenal-dependent CS (adrenal adenoma, adrenal autonomy)

               -  Etiology unknown

          5. Subjects MUST have elevated mean 24-hour UFC levels ≥1.5X ULN of assay based on a
             minimum of four measurements from adequately collected urine. Urine may be collected
             on sequential days.

          6. In addition to elevated mean UFC, presence of abnormal values from one of the
             following tests:

               -  Abnormal DST: Elevated 8 AM serum cortisol ≥1.8 ug/dL (50 nmol/L) after 1 mg
                  dexamethasone orally at 11 PM the evening prior (if not conducted already in the
                  diagnostic workup of the subject within the previous 2 months before start of
                  Screening Phase; in that case previous test results and details of conduct will
                  need to be available by the Baseline visit)

               -  Elevated late night salivary cortisol concentrations (at least two measurements)
                  &gt;ULN NOTE: For subjects with estimated glomerular filtration rate (eGFR as
                  determined by Modified Diet in Renal Disease MDRD equation) &gt;40 and &lt;60
                  mL/min/1.73 m2 in addition to meeting the UFC criteria, late night salivary
                  cortisol test results (≥2 measurements) MUST also demonstrate evidence of CS.

          7. Previously irradiated subjects with CD or CS of other etiology will be allowed as
             long as the radiation treatment occurred &gt; 4 years ago and subjects have not
             exhibited evidence for improvement in their underlying Cushing's disease for 6
             months. The total number of previously irradiated subjects enrolled in this study
             will not exceed 10.

          8. Subjects with CD or CS of other etiology who are not candidates for surgery, refuse
             surgery, or in whom surgery will be delayed for &gt;6 months. Subjects may be allowed to
             participate in the trial while awaiting surgery, but must agree to complete this
             study prior to surgery. For subjects who have already undergone surgery, a minimum of
             3 months should have elapsed before the subject can be deemed a surgical failure.

          9. Subjects on treatment for CD or endogenous CS of other etiology for whom treatment
             has been inadequate or not well tolerated must agree to the following minimum washout
             periods prior to the Baseline Visit:

               -  Inhibitors of steroidogenesis (including ketoconazole): 2 weeks

               -  Dopamine agonists: bromocriptine (2 weeks), cabergoline (8 weeks)

               -  Octreotide acetate LAR and lanreotide Autogel®: 12 weeks

               -  Lanreotide SR/long-acting pasireotide: 8 weeks

               -  Octreotide acetate (immediate release formulation) or short-acting pasireotide:
                  1 week

               -  Mifepristone (RU 486): 4 weeks

         10. Subjects on megesterol acetate (medroxyprogesterone acetate) must agree to a washout
             period of at least 6 weeks prior to the Baseline Visit

         11. A female is eligible to enter and participate in the study if she is of:

             Non-child bearing potential (i.e. physiologically incapable of becoming pregnant,
             including any female who is post-menopausal or surgically sterile). Surgically
             sterile females are defined as those with a documented hysterectomy and/or bilateral
             oophorectomy or tubal ligation.

             Post-menopausal females are defined as being amenorrhoeic for greater than 1 year
             with an appropriate clinical profile, e.g. age &gt; 45 years, in the absence of hormone
             replacement therapy. However in questionable cases, a blood sample with FSH &gt;
             40MIU/ml and estradiol &lt; 40pg/ml (&lt;140 pmol/L) is confirmatory.

             OR Child bearing potential and agrees to use highly effective methods of birth
             control while participating in the study and for 2 weeks after the study is
             completed.

         12. Fertile men must also agree to use a medically acceptable form of birth control while
             on study drug and up to 2 weeks after the study is completed.

         13. Able to comprehend and comply with procedures.

        Exclusion Criteria

        Subjects will be excluded from the study if any of the following criteria are met:

          1. Subjects with Pseudo-Cushing's syndrome based on assessment of the investigator.

          2. Subjects with cyclic Cushing's syndrome based on assessment of the investigator

          3. Subjects with a non-endogenous source of hypercortisolism such as exogenous source of
             glucocorticoids or therapeutic use of ACTH.

          4. Known inherited syndrome as the cause of hypercortisolism, including but not limited
             to multiple endocrine neoplasia Type 1, McCune Albright Syndrome and Carney Complex

          5. Subjects with adrenal carcinoma

          6. History of malignancy, other than thyroid, early stage prostate, squamous cell and
             basal cell carcinoma, within 3 years prior to the Screening Phase. Subjects with
             history of such allowed carcinoma must have a life expectancy of &gt;1 year and must be
             on stable doses of their specific therapies. Subjects with early stage prostate
             cancer undergoing no treatment due to low grade potential may be enrolled.

          7. Clinical or radiological signs of compression of the optic chiasm.

          8. Major surgery within 1 month prior to enrollment (ICF signing)

          9. Subjects with clinically significant abnormality in 12-lead ECGs during the Screening
             Phase needing medical intervention.

         10. Subjects with QTc interval of &gt;470 msec during the Screening Phase.

         11. Subjects with a history of Torsades des Pointes, or ventricular tachycardia, or
             ventricular fibrillation, or history of prolonged QT syndrome (including family
             history), or use of medications resulting in QT/QTc prolongation, or hypokalemia &lt;3.0
             meq/L.

         12. Preexisting hepatic disease; subjects with mild to moderate hepatic steatosis
             consistent with fatty infiltration (non-alcoholic fatty liver disease [NAFLD] are
             allowed).

         13. Positive for hepatitis B surface antigen (HbsAg) or positive hepatitis C test.

         14. History or symptoms of recurrent symptomatic cholelithiasis or pancreatitis.

         15. Liver function tests (LFT) must not be above the following cut-offs during the
             Screening Phase:

               -  ALT and/or AST &gt;3 X ULN

               -  Total bilirubin &gt;2 X ULN If all LFTs are within normal limits (WNL) and total
                  bilirubin (TBN) is elevated, examination of direct and indirect bilirubin may be
                  conducted. Subjects with isolated indirect TBN up to 3X ULN are presumed to have
                  Gilbert's syndrome and may be enrolled if all other LFTs are within normal
                  levels.

         16. History of documented or suspected drug-induced liver injury requiring drug
             discontinuation of ketoconazole or any azole antifungals.

         17. Pregnant or lactating women

         18. HIV-positive.

         19. History of persistent uncontrolled hypertension (&gt;180/120 mmHg) despite medical
             intervention.

         20. Subjects with hypercholesterolemia who are currently treated with atorvastatin,
             lovastatin or simvastatin and not willing or unable to change to alternative
             therapies with pravastatin, fluvastatin, and rosuvastatin within 2 weeks of start of
             the Screening Phase.

         21. Body habitus preventing repeated venipuncture as required by protocol.

         22. Subject is currently in another study or has received any investigational treatment
             (drug, biological agent or device) within 30 days or 5 half-lives of treatment,
             whichever is longer.

         23. Repeated hospitalization for hyperglycemia or any complication of hyperglycemia and
             diabetes during the last 12 months

         24. Subjects with decreased renal function as defined by eGFR &lt;40 mL/min/1.73 m2, using
             MDRD equation for estimating renal function (eGFR).

         25. Any other clinically significant medical condition, as determined by the Investigator
             that precludes enrollment and participation in the study through completion,
             including conditions that would preclude the subject from being able to follow
             instructions or to perform the necessary procedures (for example, psychiatric
             instability or severe disability).

         26. Abnormal free T4. Subjects with TSH &lt;LLN and normal free T4 are permitted to
             participate in the study.

         27. Subjects who have a history of alcohol or drug abuse in the 6 month period prior to
             enrollment.

         28. Subjects who have been treated with mitotane within 6 months of the Screening Phase.

         29. Subjects who are currently taking any H2 receptor antagonists, proton-pump
             inhibitors, or sucralfate (all of which inhibit absorption of COR-003). A list of
             orally acceptable antacids (for example, Mylanta and Maalox) will be provided, and
             can only be taken a minimum of 2 hours after dosing of COR-003.

         30. Subjects who receive any prohibited concomitant medication:

               -  Weight loss medications (prescription or over the counter)

               -  Acetaminophen &gt;3 g total daily dose (due to increased hepatotoxicity)

               -  Co-administration of strong inducers or inhibitors of CYP3A4 enzyme system that
                  may interfere with the metabolism of COR-003 and cannot be discontinued prior to
                  first dose

               -  The following herbal medicines are prohibited: St John's Wort, echinacea,
                  gingko, goldenseal, yohimbe, red rice yeast, danshen, silybum marianum, Asian
                  ginseng, schissandra sphenanther, shankhapushi, and Asian herb mixture (Xiao
                  chai hu tang and Salboku-to).

               -  Topical or inhaled steroids

               -  Carbamazipine, fenofibrate, carbenoxolone.

               -  Ingestion of genuine licorice.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredric J Cohen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cortendo AB</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fredric J Cohen, MD</last_name>
    <phone>610-254-9200</phone>
    <email>SONICStrial@cortendo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Advanced Research</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shohreh Movahedi, RN</last_name>
      <phone>562-867-8195</phone>
      <email>Shohrehm@advmedresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Glorina Lim</last_name>
      <phone>562-867-8195</phone>
      <email>glo@advmedresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Perley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayman Ansari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krishna Patel</last_name>
      <phone>310-825-5874</phone>
      <email>KrishnaPatel@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nvard Sisliyan</last_name>
      <phone>310-825-5874</phone>
      <email>Nsisliyan@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony Heaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Metabolic Research Center</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagrario Olmos-Garcia</last_name>
      <phone>805-658-8460</phone>
      <email>sagy68@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Chochinov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fernando Bril</last_name>
      <phone>352-273-8646</phone>
      <email>Fernando.Bril@medicine.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Valerie Myrick</last_name>
      <phone>352-273-8662</phone>
      <email>Valerie.Myrick@medicine.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hans Ghayee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kenneth Cusi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Lackner</last_name>
      <phone>954-487-2546</phone>
      <email>lacknep@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Jorge Canedo</last_name>
      <phone>954 659-5861</phone>
      <email>canedoj@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Pascual De Santis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oyinkan Kusemiju, MPH</last_name>
      <phone>410-955-2812</phone>
      <email>Okusemi1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Roberto Salvatori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen J.P. Liebert</last_name>
      <phone>617-726-7473</phone>
      <email>kpulaski@partners.org</email>
    </contact>
    <investigator>
      <last_name>Beverly Biller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tim Muth</last_name>
      <phone>734-615-8914</phone>
      <email>tmuth@med.umich.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nya Greenstone, MD</last_name>
      <phone>734 615 8914</phone>
      <email>ngreenst@med.umich.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Auchus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico HSC</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele A Spear, MC/MFCT, CCRC</last_name>
      <phone>505-272-9898</phone>
      <email>MSpear@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pascal Stirnimann</last_name>
      <phone>505-272-6057</phone>
      <email>pstirnimann@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Patricia Kapsner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Lovato, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Cohen</last_name>
      <phone>646-888-1365</phone>
      <email>cohenv@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Eliza Geer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Surckla</last_name>
      <phone>216-444-3955</phone>
      <email>asurckla@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Ned Kennedy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Howell</last_name>
      <phone>614-688-3785</phone>
      <email>Angela.Howell@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Rogers, MS</last_name>
      <phone>(614) 688-6885</phone>
      <email>Kelly.Rogers@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lawrence Kirschner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luma Ghalib, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley McCartney</last_name>
      <phone>503-494-7469</phone>
      <email>nsg@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Williams</last_name>
      <phone>503-494-9546</phone>
      <email>nsg@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Maria Fleseriu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Yedinak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shirley McCartney, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-5160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eileen Markmann</last_name>
      <phone>215-662-4449</phone>
      <email>Eileen.Markmann@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Snyder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Neuroendocrinology Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Cisar</last_name>
      <phone>412-359-6538</phone>
      <email>jcisar@aghendo.com</email>
    </contact>
    <investigator>
      <last_name>Murray Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann Minnock, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital, Hallett Center for Diabetes and Endocrinology</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Conti-Dutko</last_name>
      <phone>401-444-3420</phone>
      <email>Jconti@lifespan.org</email>
    </contact>
    <contact_backup>
      <last_name>Pharron Niemann</last_name>
      <email>Pharonn.niem@lifespan.org</email>
    </contact_backup>
    <investigator>
      <last_name>Geetha Gopalakrishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Correa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrine Center of Houson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Perea</last_name>
      <email>Perea.research@endocrinecenterhouston.com</email>
    </contact>
    <contact_backup>
      <last_name>Louise Duce</last_name>
      <phone>713-973-3426</phone>
      <email>duce.research@endocrinecenterhouston.com</email>
    </contact_backup>
    <investigator>
      <last_name>Amer Al-Karadsheh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Hospital, Swedish Pituitary Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Wood, CCRP</last_name>
      <phone>206-320-7115</phone>
      <email>becky.wood@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Yuen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kelley Moloney, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Mercado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora Monteyne</last_name>
      <phone>32 2 4774686</phone>
      <email>Dora.monteyne@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Brigitte Velkeniers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven Department of Endocrinology</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Achten</last_name>
      <phone>+3216348554</phone>
      <email>sophie.achten@uzleuven.be</email>
    </contact>
    <contact_backup>
      <last_name>Hilde Morobé</last_name>
      <phone>+32 16 34 03 19</phone>
      <email>hilde.morobe@uzleuven.be</email>
    </contact_backup>
    <investigator>
      <last_name>Marie Bex, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Specialized Hospital for Active Treatment in Endocrinology (USHATE)</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Atanaska Elenkova</last_name>
      <phone>359 888 719 801</phone>
      <email>atanaskae@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ivayla Tsotova, MD</last_name>
      <phone>359 888 099 659</phone>
      <email>dr_uzunova@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sabina Zaharieva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Culver</last_name>
      <phone>780-407-6135</phone>
      <email>stephen.culver@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Constance Chik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Pauls Hospital/Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerri Klein</last_name>
      <phone>604.875-5232</phone>
      <phone_ext>62413</phone_ext>
      <email>gklein@bcdiabetes.ca</email>
    </contact>
    <investigator>
      <last_name>Ehud Ur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Johnson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Dallaire</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>12914</phone_ext>
      <email>Suzanne.dallaire.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Helene Langelier</last_name>
      <phone>514-890-8000</phone>
      <email>Helene.Langelier.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Andre Lacroix, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filip Gabalec</last_name>
      <phone>+420605522516</phone>
      <email>filip.gabalec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jan Čáp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anrea Valentová</last_name>
      <email>andrea.valentova@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Michal Krsek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ludmila Brunerova, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jan Gojda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles University U</name>
      <address>
        <city>Praha</city>
        <zip>128 08</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Pacnerová,</last_name>
      <phone>+420 723 719 575</phone>
      <email>pacnerovajana@seznam.cz</email>
    </contact>
    <contact_backup>
      <last_name>Radka Vacková</last_name>
      <phone>+420 22496 2973</phone>
      <email>rvackova@post.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Václav Hana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mikuláš Kosák, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Václav Hana, Jr., MUDr. Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lone Vad</last_name>
      <phone>45 78462057</phone>
      <email>lone.vad@ki.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ann Gade</last_name>
      <phone>45 78462054</phone>
      <email>alg@clin.au.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Løgstrup Poulsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet,Copenhagen University Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Finnemann</last_name>
      <phone>45 35456751</phone>
      <email>Anja.Elisabeth.Finnemann-Platz.01@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Ulla Feldt-Rasmussen, MD, DSMc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aase Krogh Rasmussen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Dryer</last_name>
      <phone>45 21254595</phone>
      <email>tina.dreyer.01@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Caroline Kistorp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Louise Johansen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ewa Romanczuk</last_name>
      <phone>45 65413612</phone>
      <email>ewa.romanczuk@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Vibe Vestergaard</last_name>
      <phone>+45 65413612</phone>
      <email>Vibe.vestergaard@rsyd.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Marianne Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dorte Glintborg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la CONCEPTION, Service d'Endocrinologie, Diabète et Maladies Métaboliques</name>
      <address>
        <city>Cedex</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mouna Sahnoun-Fathallah</last_name>
      <phone>33491383479</phone>
      <email>mouna.sahnoun@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Brue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble, Hôpital Nord,</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maty Diop Kane</last_name>
      <phone>33 (0)6 24 46 66 54</phone>
      <email>MDiop@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Combeau</last_name>
      <phone>(33) 4 76 76 55 63</phone>
      <email>ECombeau@chu-grenoble.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Chabre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Laure Coulon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Muller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre de Réference Maladies Rares de la Surrénale, service des maladies endocriniennes et métaboliques, Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Niati</last_name>
      <phone>33 01 58 41 19 02</phone>
      <email>Tanya.niati@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Guignat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bertherat Jerome, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux, USN Haut-Levêque</name>
      <address>
        <city>Pessac cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cazenave</last_name>
      <phone>05.57.65.62.77</phone>
      <email>sarah.cazenave@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Achkir Rkia</last_name>
      <phone>33 5 57 62 32 52</phone>
      <email>rkia.achkir@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Antoine Tabarin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Laure Nunes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Hautepierre</name>
      <address>
        <city>Strassbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luz Siegel-Marc</last_name>
      <phone>33 3 88 11 51 47</phone>
      <email>luz.siegel@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Veronique Wietta</last_name>
      <phone>33 3 88 12 75 71</phone>
      <email>Veronique.WETTA@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Bernard Goichot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luca Florina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Zopf</last_name>
      <phone>49 30 450 51 40 19</phone>
      <email>Kathrin.Zopf@charite.de</email>
    </contact>
    <investigator>
      <last_name>Christian Strasburger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Kienitz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Med Clinic I - University of Lueback</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betina Fink</last_name>
      <phone>49 (0)451-500-44142</phone>
      <email>betina.fink@uksh.de</email>
    </contact>
    <investigator>
      <last_name>Georg Brabant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der LMU</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Schmid</last_name>
      <phone>49 89 4400-5-2414</phone>
      <email>Susanne_Schmid@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Rita Schwaiger</last_name>
      <phone>49 89 44005-2488</phone>
      <email>rita.schwaiger@med.uni-muenchen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jochen Schopohl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katharina Schilbach, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sylvere Stormann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Max-Planck-Institute of Psychatry, Clinical Neuroendocrinology</name>
      <address>
        <city>Munich</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mareike Stieg</last_name>
      <phone>00 49 89 30622364</phone>
      <email>mareike_stieg@psych.mpg.de</email>
    </contact>
    <investigator>
      <last_name>Günter Stalla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Auer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hospital Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martina Graesl</last_name>
      <phone>49 931 201 39716</phone>
      <email>Graesl_M@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Stefanie Hahner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timo Deutschbein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MH- Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <zip>H-1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Hubina, MD</last_name>
      <phone>36-1-475-2790</phone>
      <email>ehubina@gmail.com</email>
    </contact>
    <investigator>
      <last_name>László Kovács, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miklós Goth, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bnail Zion Medical Center Institute of Endocrinology &amp; Metabolism</name>
      <address>
        <city>Haifa</city>
        <zip>31048</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michal Yeiches</last_name>
      <phone>972-52-8283062</phone>
      <email>yeiches@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Julia Sterlin</last_name>
    </contact_backup>
    <investigator>
      <last_name>Leonard Saiegh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute of Endocrinology &amp; Metabolism, Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meira Weiss</last_name>
      <phone>972-3-9376927</phone>
      <email>meirawe@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Liat Rot</last_name>
      <phone>972-3-9376927</phone>
      <email>Liatro3@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Ilan Shimon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center, Endocrinology &amp; Metabolism</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miri Margaliot</last_name>
      <phone>972526110243</phone>
      <email>mirim@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Yona Greenman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Zefat</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agra Nataly</last_name>
      <email>nataly.ag@ziv.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Faiad Adawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera-Universitaria Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Martino</last_name>
      <phone>+39 071 5964741</phone>
      <email>mariannamartino88@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giorgio Arnaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grazia Michetti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Genova</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico Gatto, MD</last_name>
      <phone>390103538886</phone>
      <email>fedgatto@hotmail.it</email>
    </contact>
    <investigator>
      <last_name>Diego Ferone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Federico Gatto, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miryam Talco, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Endocrinologia, Dipartimento di Medicina Clinica e Sperimentale</name>
      <address>
        <city>Messina</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Luisa Torre, MD</last_name>
      <phone>393474777015</phone>
      <email>m_luisa_78@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Salvatore Cannavò, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tijana Icin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Vassalli</last_name>
      <phone>39 3933524816</phone>
      <email>sara.vassalli@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Paola Loli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Auxologico Italiano</name>
      <address>
        <city>Milan</city>
        <zip>20149</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Ambrogio, MD</last_name>
      <phone>3902619113035</phone>
      <email>albertoambrogio@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Francesca Pecori-Giraldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Naples Federico II</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica De Leo, MD</last_name>
      <phone>39 3488583899</phone>
      <email>monicadeleo25@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rosario Pivonello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Davide Lacuaniello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Cristina De Martino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessia Cozzolino, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SCDU Medicina Interna I Università di Torino Dipartimento di Scienze Cliniche e Biologiche</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Perotti, MD</last_name>
      <phone>011-399026513</phone>
      <email>oncotrial.sanluigi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Massimo Terzolo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Pia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppe Reimondo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Padua</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora Albiger, MD</last_name>
      <phone>+390498214270</phone>
      <email>nalbiger@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Carla Scaroni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University, Leiden University Medical Center, Dept. of Endocrinology</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmine Abdalla</last_name>
      <phone>071-5262840</phone>
      <email>J.Abdalla@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Sabrina Hendriksen</last_name>
      <phone>31 715262840</phone>
      <email>S.Hendriksen@lumc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Nienke Biermasz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Femke Van Haalen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC, Dpt. Of Internal Medicine, Division of Endocrinology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sjaan Poldermans</last_name>
      <phone>0031-10 703 15 98</phone>
      <email>b.poldermans@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Richard Feelders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Terpa Sp.z.o.o</name>
      <address>
        <city>Lublin</city>
        <zip>20-333</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Silik</last_name>
      <phone>48 81 442 7272</phone>
      <email>beata.siwik16@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Beata Matyjaszek-Matuszek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monika Lenart-Lipińska, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Heliodora Swiecickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu</name>
      <address>
        <city>Poznan</city>
        <zip>60-355</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elżbieta Wrotkowska</last_name>
      <phone>48 660 851 500</phone>
      <email>elawrot@vp.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Ruchala</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tamara Nowocien</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadja Sawicka-Gutaj</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic: Reuma Centrum</name>
      <address>
        <city>Warszawa</city>
        <zip>04-305</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waldemar Kapusta, MD</last_name>
      <phone>48 22 225 0110</phone>
      <email>wkapusta@wim.mil.pl</email>
    </contact>
    <investigator>
      <last_name>Przemysław Witek, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1</name>
      <address>
        <city>Wroclaw</city>
        <zip>50367</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Kaluzny, MD</last_name>
      <phone>48 71 784 24 32</phone>
      <email>kmaluzny@poczta.onet.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Bolanowski, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcin Kaluzny, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eliza Kubicka</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aleksandra Jawiarczyl-Przbylowska</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instytut Centrum Zdrowia Matki Polki</name>
      <address>
        <city>Łódź</city>
        <zip>93-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arkadiusz Zygmunt, MD</last_name>
      <phone>48 502 892 628</phone>
      <email>arkadiusz.zygmunt@umed.lodz.pl</email>
    </contact>
    <contact_backup>
      <last_name>Magdalena Stasiak, MD</last_name>
      <phone>48 502 049 292</phone>
      <email>mstasiak33@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Andrzej Lewinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arkadiusz Zygmunt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magdalena Stasiak, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mila Pantovic</last_name>
      <phone>38163 7051376‬</phone>
      <email>millapantovic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sandra Pekic-Djurdjevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dragana Miljic, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Drita Skrbic</last_name>
      <phone>381 (64) 8059078</phone>
    </contact>
    <investigator>
      <last_name>Milica Medic-Stojanoska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tijana Icin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universidad De La Ribera</name>
      <address>
        <city>Alzira-Valencia</city>
        <zip>46600</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeles Martorell</last_name>
      <phone>34 962458580</phone>
      <email>mamartorell@hospital-ribera.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Fajardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jose Gomez Vela, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pedro Riesgo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endocrinologia, Hospital Sant Pau,Universitat Autònoma de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Roig</last_name>
      <phone>34-620-975256</phone>
      <email>oroig@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Susan Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Aulinas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Rosa Alhambra Expósito</last_name>
    </contact>
    <investigator>
      <last_name>Maria Galvez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paloma Moreno, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Conxo</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Isabel Castro Pais</last_name>
      <phone>34981951609</phone>
      <email>naisabel.castro@usc.es</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Santos Conde</last_name>
      <phone>34672124923</phone>
      <email>dasaco.ct@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Felipe Casanueva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Tiberg Persson</last_name>
      <phone>+46-3428396</phone>
      <email>jenny.c.tiberg@vgregion.se</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Kall</last_name>
      <email>Kristina.cid.kall@vgregion.se</email>
    </contact_backup>
    <investigator>
      <last_name>Gudmundur Johannsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oskar Ragnarsson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catharina Grimming</last_name>
      <phone>46 8-51772456</phone>
      <email>catharina.grimming@karolinska.se</email>
    </contact>
    <contact_backup>
      <last_name>Anette Härström</last_name>
      <phone>46-851772736</phone>
      <email>Anette.harstrom@karolinska.se</email>
    </contact_backup>
    <investigator>
      <last_name>Charlotte Höybye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital (Sweden)</name>
      <address>
        <city>Uppsala</city>
        <zip>S-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Forsgren</last_name>
      <phone>46-18 611 44 16</phone>
      <email>Maria.forsgren@akademiska.se</email>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Olsson</last_name>
      <phone>46-18 611 27 02</phone>
      <email>elisabet.olsson@akademiska.se</email>
    </contact_backup>
    <investigator>
      <last_name>Britt Edén Engström, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cemile Bathelt</last_name>
      <phone>41 61 556 54 07</phone>
      <email>cemile.bathelt@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Mirjam Christ-Crain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bezmi Alem Vakıf Üniversitesi Endokrinoloji Bölümü Adnan</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozcan Karaman</last_name>
      <phone>90 533 613 70 58</phone>
      <email>Ozcankaraman@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ertugrul Tasan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Zak</last_name>
      <phone>44 (0) 207 882 5657</phone>
      <email>a.zak@qmul.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Jane Pheby</last_name>
      <email>j.m.pheby@qmul.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>William Drake, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manish Saxena, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Shiel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Gordon, MD</last_name>
      <phone>020 3299 3034</phone>
      <phone_ext>KH 3035</phone_ext>
      <email>nadia.gordon@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Penny Hammond, MD</last_name>
      <phone>0203299 1851</phone>
      <email>Phammond3@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Aylwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Mawn</last_name>
      <phone>0161 906 7500</phone>
      <email>Stephen.Mawn@wtcrf.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Zamora</last_name>
      <phone>+44 (0) 161 901 2683</phone>
      <email>daniel.zamora@cmft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>David Ray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tolga Turgt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine Hurst</last_name>
      <phone>0161 446 8437</phone>
      <email>Janine.Hurst@christie.nhs.uk; janinehurst@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Grace Ensah</last_name>
      <phone>0161 446 8132</phone>
      <email>Grace.Ensah@christie.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Trainer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Blood</last_name>
      <phone>0161 2065205</phone>
      <email>janet.blood@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Tara Kearney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sumithra Giritharan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Georgia</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 8, 2017</lastchanged_date>
  <firstreceived_date>April 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
